Ayumi Hashimoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ayumi Hashimoto has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- A. Kate Sasser
Genmab, Princeton, NJ, USA
1 shared publication - Anil K. Rustgi
Columbia University Irving Medical Center 3 Division of Digestive and Liver Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons New York, New York
1 shared publication - Christopher Chiu
Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA, 19477, USA
1 shared publication - Dmitry I. Gabrilovich
AstraZeneca, ICC, Early Oncology R&D, Gaithersburg, USA
1 shared publication - Eric W. Lin
Mass General Cancer Center, Harvard Medical School, Charlestown, Massachusetts
1 shared publication - George A. Dominguez
Anixa Biosciences, Inc., San Jose, CA, USA
1 shared publication
Latest Publications
- Open Access
- 22 March 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (6)
CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients
BACKGROUND. Myeloid-derived suppressor cells (MDSCs) are a population of immature immune cells with several protumorigenic functions. CD38 is a transmembrane receptor–ectoenzyme expressed by MDSCs in murine models of esophageal cancer. We hypothesized that CD38 could be expressed on MDSCs in human colorectal cancer (CRC), which might allow for a new perspective on therapeutic targeting of human MDSCs with anti-CD38 monoclonal antibodies in this cancer. METHODS. Blood samples were collected from 41 CRC patients and 8 healthy donors, followed by peripheral blood mononuclear cell (PBMC) separation. Polymorphonuclear (PMN-) and monocytic (M-) MDSCs and CD38 expression levels were quantified by flow cytometry. The immunosuppressive capacity of M-MDSCs from 10 CRC patients was validated in a mixed lymphocyte reaction (MLR) assay. RESULTS. A significant expansion of CD38 + M-MDSCs and a trend of expansion of CD38 + PMN-MDSCs (accompanied by a trend of increased CD38 expression on both M- and PMN-MDSCs) were observed in PBMCs of CRC patients when compared with healthy donors. The CD38 + M-MDSCs from CRC patients were found to be immunosuppressive when compared with mature monocytes. CD38 + M- and PMN-MDSC frequencies were significantly higher in CRC patients who previously received treatment when compared with treatment-naive patients. CONCLUSIONS. This study provides a rationale for an attempt to target M-MDSCs with an anti-CD38 monoclonal antibody in metastatic CRC patients. FUNDING. NCI P01-CA14305603, the American Cancer Society, Scott and Suzi Lustgarten Family Colon Cancer Research Fund, Hansen Foundation, and Janssen Research and Development.
- 22 March 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (6)
Open AccessCD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients
BACKGROUND. Myeloid-derived suppressor cells (MDSCs) are a population of immature immune cells with several protumorigenic functions. CD38 is a transmembrane receptor–ectoenzyme expressed by MDSCs in murine models of esophageal cancer. We hypothesized that CD38 could be expressed on MDSCs in human colorectal cancer (CRC), which might allow for a new perspective on therapeutic targeting of human MDSCs with anti-CD38 monoclonal antibodies in this cancer. METHODS. Blood samples were collected from 41 CRC patients and 8 healthy donors, followed by peripheral blood mononuclear cell (PBMC) separation. Polymorphonuclear (PMN-) and monocytic (M-) MDSCs and CD38 expression levels were quantified by flow cytometry. The immunosuppressive capacity of M-MDSCs from 10 CRC patients was validated in a mixed lymphocyte reaction (MLR) assay. RESULTS. A significant expansion of CD38 + M-MDSCs and a trend of expansion of CD38 + PMN-MDSCs (accompanied by a trend of increased CD38 expression on both M- and PMN-MDSCs) were observed in PBMCs of CRC patients when compared with healthy donors. The CD38 + M-MDSCs from CRC patients were found to be immunosuppressive when compared with mature monocytes. CD38 + M- and PMN-MDSC frequencies were significantly higher in CRC patients who previously received treatment when compared with treatment-naive patients. CONCLUSIONS. This study provides a rationale for an attempt to target M-MDSCs with an anti-CD38 monoclonal antibody in metastatic CRC patients. FUNDING. NCI P01-CA14305603, the American Cancer Society, Scott and Suzi Lustgarten Family Colon Cancer Research Fund, Hansen Foundation, and Janssen Research and Development.